SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications.
+ 1 more risk
Adequate balance sheet and overvalued.
Share Price & News
How has SELLAS Life Sciences Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SLS's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: SLS underperformed the US Biotechs industry which returned -0.7% over the past year.
Return vs Market: SLS underperformed the US Market which returned -12.7% over the past year.
Price Volatility Vs. Market
How volatile is SELLAS Life Sciences Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StHere's Why We're A Bit Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Situation
5 months ago | Simply Wall StSELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely
9 months ago | Simply Wall StWhat Kind Of Shareholders Own SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)?
Is SELLAS Life Sciences Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SLS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SLS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SLS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: SLS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SLS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SLS is good value based on its PB Ratio (1.6x) compared to the US Biotechs industry average (2.5x).
How is SELLAS Life Sciences Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SLS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SLS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SLS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if SLS's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if SLS's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SLS's Return on Equity is forecast to be high in 3 years time
How has SELLAS Life Sciences Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SLS is currently unprofitable.
Growing Profit Margin: SLS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SLS is unprofitable, and losses have increased over the past 5 years at a rate of -23.5% per year.
Accelerating Growth: Unable to compare SLS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SLS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: SLS has a negative Return on Equity (-316.63%), as it is currently unprofitable.
How is SELLAS Life Sciences Group's financial position?
Financial Position Analysis
Short Term Liabilities: SLS's short term assets ($8.2M) exceed its short term liabilities ($5.3M).
Long Term Liabilities: SLS's short term assets ($8.2M) exceed its long term liabilities ($5.2M).
Debt to Equity History and Analysis
Debt Level: SLS is debt free.
Reducing Debt: SLS had no debt 5 years ago.
Inventory Level: SLS has a low level of unsold assets or inventory.
Debt Coverage by Assets: SLS's debt is not covered by short term assets (assets are -294.4x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SLS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SLS has less than a year of cash runway if free cash flow continues to reduce at historical rates of -25% each year
What is SELLAS Life Sciences Group's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SLS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SLS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SLS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SLS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Angelos M. Stergiou, MD, ScD h.c., is the Founder, President and Chief Executive Officer of SELLAS Life Sciences Group AG (formerly, Sellas Inc.). Dr. Stergiou served as Vice President of Clinical Dev ...
CEO Compensation Analysis
Compensation vs Market: Angelos's total compensation ($USD1.24M) is above average for companies of similar size in the US market ($USD605.16K).
Compensation vs Earnings: Angelos's compensation has increased whilst the company is unprofitable.
|Executive VP||2yrs||US$630.68k||no data|
|Chief Medical Officer||0.75yr||US$783.30k||no data|
|VP of Finance & Corporate Controller & Interim Principal Accounting Officer||no data||no data||0.000010% $1.3|
|Chief Operating Officer||3.42yrs||no data||no data|
|Senior VP of Clinical Development||no data||no data||no data|
|Director of Clinical and Business Operations||no data||no data||no data|
|Head of Clinical Operations||no data||no data||no data|
|Vice President of Legal Affairs||no data||no data||no data|
Experienced Management: SLS's management team is considered experienced (2.7 years average tenure).
|Director||no data||US$122.63k||no data|
|Director||no data||US$124.00k||no data|
|Director||no data||US$156.88k||no data|
|Member of Scientific Advisory Board||4.33yrs||no data||no data|
|Chairman of Scientific Advisory Board||1.75yrs||no data||no data|
|Member of Scientific Advisory Board||3.33yrs||no data||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
|Member of Scientific Advisory Board||4.33yrs||no data||no data|
Experienced Board: SLS's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 878.3%.
SELLAS Life Sciences Group, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: SELLAS Life Sciences Group, Inc.
- Ticker: SLS
- Exchange: NasdaqCM
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$12.630m
- Shares outstanding: 6.72m
- Website: https://www.sellaslifesciences.com
Number of Employees
- SELLAS Life Sciences Group, Inc.
- 15 West 38th Street
- 10th Floor
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RXK3||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jan 2018|
|SLS||NasdaqCM (Nasdaq Capital Market)||Yes||Common Shares||US||USD||Jan 2018|
SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/30 03:54|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.